Targeting a specific protein in breast cancer to improve treatment outcomes
Official title: Development of chemical probe targeting NSD3 SET domain in breast cancer
Funded at University of Michigan at Ann Arbor · NIH-11030849 · Data updated 2026-11-12
This study is looking at new ways to create medicines that can block a protein called NSD3, which is linked to breast cancer growth, to help develop better treatment options for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $572,327 |
| NIH project number | 5R01CA285304-02 |
| Project ID | NIH-11030849 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are breast cancer patients whose tumors exhibit amplifications of the NSD3 gene.
✕Less likely to help
Patients without breast cancer or those whose tumors do not have NSD3 amplifications may not benefit from this research.
What this research studies
This research focuses on developing small molecule chemical probes that specifically target the NSD3 SET domain, a protein implicated in breast cancer progression. By understanding how this protein contributes to tumor growth, the researchers aim to create effective inhibitors that can block its activity. The approach involves testing these compounds in breast cancer models, particularly those with NSD3 amplifications, to evaluate their impact on cancer cell growth and survival. Patients may benefit from new treatment options that arise from this innovative strategy.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for breast cancer patients with NSD3 amplifications.
How similar studies have gone: While targeting similar proteins in cancer has shown promise, this specific approach to inhibit NSD3 is novel and has not been extensively tested in prior studies.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Cierpicki, Tomasz — University of Michigan at Ann Arbor
- Study coordinator: Cierpicki, Tomasz
Related research
Other NIH-funded projects on the same topics.
-
Improving Breast Cancer Guideline Adherence in Nigeria
Aimed at helping doctors in Nigeria follow international guideline-based breast cancer care to improve outcomes for women with breast cancer.
-
Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry
This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.
-
Translational breast cancer research to improve treatment options
A comprehensive program at Baylor College of Medicine is focusing on breast cancer; researchers will advance targeted therapies and biomarkers to help patients with aggressive or hard-to-treat forms.
-
Cancer Pain Management for Asian American Breast Cancer Survivors with Depressive Symptoms
A technology-based program helps Asian American breast cancer survivors with depressive symptoms manage chronic pain more effectively from home using a web app and mobile tools.
-
Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans
A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.
-
Gut bacteria and metabolites linked to breast density and cancer risk
A small, patient-friendly study will explore whether gut bacteria and their byproducts are connected to high breast density, which can raise cancer risk and make screening less accurate.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.